Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.34 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545218 | 0.98 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNANPC1HPGDRAB9A | |
| SCHEMBL16967925 | 0.82 | LMNA (0.36) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL11417303 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNANPC1HPGDRAB9A | |
| SCHEMBL6836877 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1HPGDRAB9A | |
| SCHEMBL2449598 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1HPGDRAB9A | |
| SCHEMBL18726773 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1HPGDRAB9A | |
| SCHEMBL4185553 | 0.77 | SETD7 (0.43) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL20097985 | 0.76 | LMNA (0.33) | SMN1; SMN2LMNA | |
| SCHEMBL5642488 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNARAB9AALDH1A1GAA | |
| SCHEMBL15804830 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNANPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492347-B2 | Fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2022-11-08 | — | — | US | disclosed |
| EP-3749659-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| CN-111954668-A | Fused thiophene derivative and use thereof | 埃尼奥制药公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| WO-2017158151-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017109088-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-06-29 | — | — | WO | disclosed |
| WO-2016207081-A1 | IMINE DERIVATIVES AS HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207082-A1 | HERBICIDAL HALOALKYLSULPHONAMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207083-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-29 | — | — | WO | disclosed |
| EP-1047695-B1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| US-6291475-B1 | 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1047695-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999031100-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | SMN1; SMN2 4008/4885LMNA 4703/4885NPC1 407/4885 |
| US-11492347-B2 | Fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | SMN1; SMN2 4008/4885LMNA 4703/4885NPC1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.